– Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee – – He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries – – His deal sheet includes transactions totaling more than USD 2.7 billion in CNS and beyond – NEW YORK and BERLIN…

Source

Previous articleBetterLife Announces Closing of Private Placement
Next articlePT377 – Integrative Medicine: Health, Wellness, and Psychedelics